ViCapsys Life Sciences today announced the appointment of Mr. Richard Rosenblum, Dr. Colleen Delaney, and Mr. Charles Farrahar to the Company's Board of Directors, effective September 22, 2022...
ViCapsys Life Sciences, Inc., (OTC:VICP) (“ViCapsys” or the “Company”) announced the appointment of Federico Pier as Chief Executive Officer of ViCapsys, effective February 15, 2022. Mr. Pier had been serving as interim President & CEO since August 2020.
We previously demonstrated that the incorporation of the chemokine CXCL12 into alginate microbeads supported long-term survival of microencapsulated auto-, allo-, and xenogeneic islets in murine models of diabetes without systemic immune suppression. The purpose of this study was to test whether CXCL12 could abrogate foreign body responses (FBRs)...
Alloantigen specific T cells have been shown to be required for allograft rejection. The chemokine, stromal cell derived factor-1 (SDF-1) at high concentration, has been shown to act as a T-cell chemorepellent and abrogate T-cell infiltration into a site of antigen challenge in vivo via a mechanism termed fugetaxis or chemorepulsion. We postulated that this mechanism could be exploited therapeutically and that allogeneic cells engineered to express a chemorepellent protein would not be rejected...
Islet transplantation represents a potentially curative approach for individuals with Type I Diabetes....
Pancreatic β‐cell replacement by islet transplantation for the treatment of type 1 diabetes (T1D) is currently limited by donor tissue scarcity and the requirement for lifelong immunosuppression...
Abstract: Type 1 diabetes (T1D) is a complex multifactorial disease characterized by autoimmune destruction of insulin producing pancreatic β cells...